Source link : https://www.newshealth.biz/health-news/marstacimab-gets-fda-nod-for-hemophilia-a-or-b-without-inhibitors/
The FDA approved marstacimab (Hympavzi) for routine prophylaxis to prevent or reduce bleeding episodes in adults and adolescents ages 12 years and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors, the agency said Friday. Marstacimab targets the Kunitz 2 domain of tissue factor pathway inhibitor (TFPI), a natural […]
Author : News Health
Publish date : 2024-10-11 21:24:09
Copyright for syndicated content belongs to the linked Source.
Categories